Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.41 |
| ▸ | ROS1 | P08922 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003530 | 0.84 | CNR1 (0.49) | EPHX2SLC5A1NOTUM | |
| SCHEMBL4003524 | 0.84 | CNR1 (0.49) | EPHX2SLC5A1NOTUM | |
| SCHEMBL4006871 | 0.76 | KMT2A (0.59) | — | |
| SCHEMBL4006881 | 0.76 | KMT2A (0.59) | — | |
| SCHEMBL12894868 | 0.75 | NOTUM (0.50) | EPHX2PTGESNOTUM | |
| SCHEMBL23484542 | 0.74 | MAP4K4 (0.49) | EPHX2CHRM4EPHX1 | |
| SCHEMBL15106610 | 0.73 | EPHX2 (0.45) | EPHX2CHRM4PTGESNOTUMEPHX1 | |
| SCHEMBL15106609 | 0.73 | EPHX2 (0.45) | EPHX2CHRM4PTGESNOTUMEPHX1 | |
| SCHEMBL612468 | 0.72 | ALDH1A1 (0.52) | EPHX2NOTUM | |
| SCHEMBL5950926 | 0.72 | EPHX2 (0.42) | EPHX2CHRM4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | claimed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | EPHX2 788/4885SLC5A1 90/4885CHRM4 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.